Published in Heart Disease Weekly, March 14th, 2004
The company plans to work with the FDA to review and address their requirements.
Since February 2003, the company has been processing tissues without the decellularized SG technology.
Revenues from CryoValve SG processed heart valves were not included in the company's financial guidance for 2004; therefore, the company's previously announced...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Heart Disease Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.